Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novo Nordisk A/S Clear all
Terminated Phase 2 Interventional Results available

Efficacy of Liraglutide Therapy in Patients With IPAA

NCT04763564
View directory record Official record
Conditions
Pouchitis, Irritable Pouch Syndrome
Interventions
Liraglutide Pen Injector, Placebo Pen Injector
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

NCT01885208
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Pell City, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 13, 2026, 5:34 PM EDT
Completed No phase listed Observational

GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

NCT01950650
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
No treatment given, survey
Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 4 Interventional Results available

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

NCT00998335
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

NCT06642571
View directory record Official record
Conditions
Obesity
Interventions
NNC0519-0130 B, NNC0519-0130 C
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 13, 2026, 5:34 PM EDT
Completed No phase listed Observational

Diabetes Attitudes Wishes and Needs

NCT01507116
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Relatives to/Carers of Patients, Healthcare Professionals
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
8,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 13, 2026, 5:34 PM EDT
Terminated Phase 3 Interventional

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

NCT05636176
View directory record Official record
Conditions
Heart Failure
Interventions
Ziltivekimab, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
172
States / cities
Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 5:34 PM EDT
Completed No phase listed Observational

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia

NCT03660774
View directory record Official record
Conditions
Haemophilia A, Haemophilia B
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 21 Years · Male only
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 13, 2026, 5:34 PM EDT
Not listed Phase 2 Interventional

Growth Hormone Replacement Therapy for Retried Professional Football Players

NCT04121780
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Interventions
Growth Hormone, Placebo
Biological · Other
Lead sponsor
Center for Neurological Studies
Other
Eligibility
18 Years to 76 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Results available

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

NCT04279613
View directory record Official record
Conditions
Type I Diabetes
Interventions
NNC0361-0041, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

NCT00914589
View directory record Official record
Conditions
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
catridecacog, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Atlanta, Georgia • Durham, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 13, 2026, 5:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

NCT07437079
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC6989-0001, Placebo (NNC6989-0001)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 13, 2026, 5:34 PM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0662-0419, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Lancaster, California • Lomita, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of DCR-AUD in Healthy Volunteers

NCT05021640
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
DCR-AUD, Placebo for DCR-AUD
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

NCT01569841
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

NCT05333107
View directory record Official record
Conditions
Healthy Volunteers; High Cholesterol
Interventions
NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Cypress, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 13, 2026, 5:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

NCT02314052
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 13, 2026, 5:34 PM EDT
Not listed No phase listed Observational

Hormone Deficiency After Brain Injury During Combat

NCT01666964
View directory record Official record
Conditions
Traumatic Brain Injury, Hypopituitarism
Interventions
Blast Traumatic Brain Injury
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 3 Interventional

Outcomes With Tight Control of Hyperglycemia in Cardiac Surgery Patients

NCT00282698
View directory record Official record
Conditions
Cardiac Surgical Procedures, Hyperglycemia
Interventions
Insulin infusion with a goal
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

NCT04074161
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Fullerton, California • Huntington Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 13, 2026, 5:34 PM EDT
Completed No phase listed Observational

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

NCT01009905
View directory record Official record
Conditions
Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 18 Years
Enrollment
22,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study of the Effect of Food on Etavopivat in Healthy Participants

NCT06433661
View directory record Official record
Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
Etavopivat
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 13, 2026, 5:34 PM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

NCT00283751
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
21
States / cities
Greenbrae, California • La Mesa, California • West Palm Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 13, 2026, 5:34 PM EDT